-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Paratek Pharmaceuticals, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2010 to 2022.
- Paratek Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2023 was -$14.6M, a 17.6% increase year-over-year.
- Paratek Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending June 30, 2023 was -$62.5M, a 27.5% increase year-over-year.
- Paratek Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$63.6M, a 7.55% decline from 2021.
- Paratek Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$59.1M, a 38.8% increase from 2020.
- Paratek Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was -$96.6M, a 24.9% increase from 2019.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)